sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Europe In Vitro Fertilization (IVF) Market by Cycle Type (Fresh Cycle, Thawed IVF Cycle, and Donor Egg IVF Cycle) and End User (Fertility Clinics, Hospitals, Surgical Centers, and Clinical Research Institutes) - Opportunity Analysis and Industry Forecast, 2014-2022

Europe In Vitro Fertilization (IVF) Market by Cycle Type (Fresh...

Home / Categories / Healthcare
Europe In Vitro Fertilization (IVF) Market by Cycle Type (Fresh Cycle, Thawed IVF Cycle, and Donor Egg IVF Cycle) and End User (Fertility Clinics, Hospitals, Surgical Centers, and Clinical Research Institutes) - Opportunity Analysis and Industry Forecast, 2014-2022
Europe In Vitro Fertilization (IVF)...
Report Code
RO1/113/1097

Publish Date
01/Dec/2016

Pages
148
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
The European IVF market is expected to reach $4,447 million in 2022 growing at a CAGR of 5.4%, from $3,054 million in 2015. Delayed pregnancy in women is a major factor that drives the European market, as the chances of conceiving lowers with age and the success rate of getting pregnant via in vitro fertilization reduces with increase in age. Other factors that accelerate the market growth are rise in infertility rate due to increase in stress levels, change in lifestyle, and fertility-related diseases.

In Europe, government regulations are favorable towards IVF treatments. The presence of regulatory and reimbursement policies such as three-parent IVF treatments and Human Fertilization and Embryo Authority (HFEA) guidelines contribute to high market growth. IVF treatments have been criticized across various regions on ethical grounds. For instance, few incidences have been reported in the past for mixing-up of embryos. Hence, the HFEA, which closely regulates the IVF treatments and research in UK, adopted the double-witness system to minimize chances of embryo mix-up in clinics. However, lack of reimbursements in Russia is expected to limit the growth of the Russian IVF market during the forecast period.

KEY BENEFITS FOR STAKEHOLDERS:

This report provides an in-depth analysis of the European IVF market across eight major countries along with cross-sectional analysis of the total number of IVF cycles performed and the total revenue generated during the forecast period.
It includes the strategies adopted by various IVF clinics and hospitals across major countries to capitalize on the latent opportunities in the market.
The projections are made by analyzing the current market trends and highlighting the market potential, in terms of value and volume, from 2014 to 2022.
Extensive analysis of the market is conducted by monitoring the top contenders.

KEY MARKET SEGMENTS:

By End User (Value and Volume)

Fertility Clinics
Hospitals
Surgical Centers
Clinical Research Institutes

By Cycle Type (Value and Volume)

Fresh Cycle (Non-Donor)
Thawed IVF Cycle (Non-Donor)
Donor Egg IVF Cycle

By Cycle Type Country Level Analysis (Value and Volume)

Germany
France
UK
Italy
Spain
Denmark
Russia
Rest of Europe

Key Companies

Thermo Fisher Scientific, Inc.
DRK Kliniken Berlin
Sun Pharmaceutical Industries Ltd.
Cadila Healthcare Ltd.
LG Life Sciences
EMD Serono Inc.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com